[go: up one dir, main page]

WO2004053100A3 - Polypeptides gp120 du virus de l'immunodeficience humaine mutants immunogenes, et leurs procedes d'utilisation - Google Patents

Polypeptides gp120 du virus de l'immunodeficience humaine mutants immunogenes, et leurs procedes d'utilisation Download PDF

Info

Publication number
WO2004053100A3
WO2004053100A3 PCT/US2003/039534 US0339534W WO2004053100A3 WO 2004053100 A3 WO2004053100 A3 WO 2004053100A3 US 0339534 W US0339534 W US 0339534W WO 2004053100 A3 WO2004053100 A3 WO 2004053100A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
methods
same
immunogenic mutant
immunodeficiency virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/039534
Other languages
English (en)
Other versions
WO2004053100A2 (fr
Inventor
Dennis R Burton
Ian Wilson
Ralph Pantophlet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Priority to AU2003300870A priority Critical patent/AU2003300870A1/en
Publication of WO2004053100A2 publication Critical patent/WO2004053100A2/fr
Publication of WO2004053100A3 publication Critical patent/WO2004053100A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a trait à des polypeptides gp120 du VIH mutants immunogènes, qui présentent au moins une mutation et possèdent au moins un épitope qui se lie de manière spécifique à des anticorps non neutralisants. L'invention concerne également des procédés de production de tels anticorps neutralisant le VIH, qui font appel à de tels polypeptides gp120 mutants immunogènes. De plus, l'invention se rapporte à des méthodes permettant d'induire une réponse d'anticorps neutralisant le VIH chez un sujet.
PCT/US2003/039534 2002-12-11 2003-12-11 Polypeptides gp120 du virus de l'immunodeficience humaine mutants immunogenes, et leurs procedes d'utilisation Ceased WO2004053100A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003300870A AU2003300870A1 (en) 2002-12-11 2003-12-11 Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43286902P 2002-12-11 2002-12-11
US60/432,869 2002-12-11
US46535003P 2003-04-24 2003-04-24
US60/465,350 2003-04-24

Publications (2)

Publication Number Publication Date
WO2004053100A2 WO2004053100A2 (fr) 2004-06-24
WO2004053100A3 true WO2004053100A3 (fr) 2004-12-29

Family

ID=32511677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/039534 Ceased WO2004053100A2 (fr) 2002-12-11 2003-12-11 Polypeptides gp120 du virus de l'immunodeficience humaine mutants immunogenes, et leurs procedes d'utilisation

Country Status (2)

Country Link
AU (1) AU2003300870A1 (fr)
WO (1) WO2004053100A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534640A (ja) * 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
WO2011028963A2 (fr) * 2009-09-03 2011-03-10 Biological Mimetics, Inc. Compositions immunogènes du vih
US11149069B2 (en) 2012-08-03 2021-10-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers
WO2014165494A1 (fr) * 2013-04-02 2014-10-09 Duke University Production de glycoprotéines d'enveloppe du vih-1 par des techniques de recombinaison
US10245313B2 (en) * 2014-10-24 2019-04-02 Versitech Limited DNA motif compounds and methods for inducing specific antibodies and cellular immunity
EP3870703A1 (fr) * 2018-10-22 2021-09-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Protéine gp120 de recombinaison à délétion de la boucle v1
TWI762925B (zh) * 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
CN117568404B (zh) * 2024-01-16 2024-03-15 四川大学华西医院 多指（趾）相关的基因片段以及动物模型构建方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US5653985A (en) * 1990-03-09 1997-08-05 Chiron Corporation Purified gp120 composition retaining natural conformation
US5814458A (en) * 1988-09-13 1998-09-29 Chiron Corporation Immunoassay methods for the detection of HIV-1 antibodies employing envelope muteins containing hypervariable domain deletions
US6103238A (en) * 1992-03-13 2000-08-15 President And Fellows Of Harvard College Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814458A (en) * 1988-09-13 1998-09-29 Chiron Corporation Immunoassay methods for the detection of HIV-1 antibodies employing envelope muteins containing hypervariable domain deletions
US5653985A (en) * 1990-03-09 1997-08-05 Chiron Corporation Purified gp120 composition retaining natural conformation
US6103238A (en) * 1992-03-13 2000-08-15 President And Fellows Of Harvard College Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies

Also Published As

Publication number Publication date
AU2003300870A8 (en) 2004-06-30
AU2003300870A1 (en) 2004-06-30
WO2004053100A2 (fr) 2004-06-24

Similar Documents

Publication Publication Date Title
WO1999033868A3 (fr) Vaccin
WO2001054719A3 (fr) Nouvelle utilisation
WO2002024149A3 (fr) Antigène
WO1999010375A3 (fr) Vaccin
WO2003039470A3 (fr) Immunogene polyvalent
WO2007099446A3 (fr) Vesicules de type virosome comprenant des antigenes derives de gp41
WO2002020554A3 (fr) Peptides vih, antigenes, compositions de vaccin, coffret de dosage immunologique et procede permettant la detection d'anticorps induits par vih
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
CA2363947A1 (fr) Peptides, antigenes du vih, compositions de vaccins afferentes, trousse de dosage immunologique et methode de detection d'anticorps induits par le vih
WO2005027836A3 (fr) Immunogene
WO2004009785A3 (fr) Proteine de fusion igg fc/hiv-gp120/c3d
WO2004053100A3 (fr) Polypeptides gp120 du virus de l'immunodeficience humaine mutants immunogenes, et leurs procedes d'utilisation
WO2003087757A3 (fr) Glycoproteines de l'enveloppe du virus d'immunodeficience humaine liees a des particules, compositions et procedes associes
WO2004108885A3 (fr) Proteines chimeres fc avec medicaments anti-vih
WO2002087614A3 (fr) Nouvelle composition
WO2005028618A3 (fr) Compositions immunogenes pour streptococcus agalactiae
WO2003092615A3 (fr) Utilisation d'anticorps anti-cd 1 pour la modulation de reponses immunitaires
WO2003049765A3 (fr) Vaccin contre des virus enveloppes et methode de production
WO2003046137A3 (fr) Immunogene du site de liaison v3-ccr5 de l'enveloppe du vih
WO2003040341A3 (fr) Anticorps contre le virus de l'hepatite a
WO2005089231A3 (fr) Activite renforcee de vaccin vih utilisant un oligonucleotide immunomodulateur de seconde generation
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO2002053587A3 (fr) Polypeptide induisant des anticorps neutralisant le vih
WO2002034909A3 (fr) Chimere de fragments de proteines synthetisee et ses methodes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP